Beone Medicines

This early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer or other solid tumors that have spread. The study aims to find the safest an…

This phase 3 study compares two drug combinations for people with untreated chronic lymphocytic leukemia (CLL). One group gets sonrotoclax plus zanubrutinib, the other gets venetoclax plus acalabrutinib. The goal is to see which combo works better at controlling the disease and c…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Abo…

This early-phase study tests a new drug called BG-C477, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About …

This study tests a new drug, BGB-16673, against standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has already been treated with both BTK and BCL2 inhibitors. About 250 participants will be randomly assigned to …

This early-phase study tests a new drug called BGB-B2033, alone or with other cancer medicines, in people with advanced liver, stomach, lung, or rare germ cell tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Abo…

This study compares an experimental drug, BGB-16673, to an approved drug, pirtobrutinib, in about 500 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer returned or didn't respond after prior treatment with a BTK inhibitor. The main go…

This study is testing an experimental drug called BG-75098, alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 105 participants will…

This early-phase study tests a new drug called BG-C0902 in people with advanced solid tumors that have not responded to other treatments. The drug is designed to target two cancer-related proteins (EGFR and MET) and deliver a chemotherapy-like payload directly to cancer cells. Th…

This study tests a new drug called BGB-16673, which breaks down a protein that helps cancer cells grow, combined with other treatments. It is for people with B-cell blood cancers (like lymphoma) that have returned or not responded to prior therapy. The study will enroll about 80 …

This study tests an experimental drug called BG-75202, alone or with other treatments, in people with advanced breast cancer or other solid tumors that have stopped responding to standard therapies. The main goals are to check safety, find the best dose, and see if the drug can s…

This study tests a new drug called sonrotoclax, alone or with other medicines, in people with a type of blood cancer (multiple myeloma) that has come back or not responded to treatment. The cancer must have a specific genetic change called t(11;14). The goal is to see if the drug…

This early-phase study tests an experimental drug called BGB-26808, either alone or combined with an immunotherapy (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe and recommended dose. About 217 …

This early-stage study tests a new drug called BGB-21447, which blocks a protein that helps cancer cells survive. It is given together with standard hormone therapy (fulvestrant) and sometimes another targeted drug (BGB-43395) to adults with HR+/HER2- breast cancer that has sprea…

This study tests an experimental drug called BGB-16673 in people with several types of B-cell cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The tri…

This study tests a new drug called BGB-16673 in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer returned or stopped responding after treatment with a BTK inhibitor. About 150 participants will receive either BGB-16673 or one of two …

This study is testing a drug called tislelizumab combined with chemotherapy as a first treatment for people with advanced stomach or esophageal cancer that cannot be removed by surgery or has spread. It focuses on racial and ethnic minority groups in the US, including Black, Hisp…

This early-phase study tests a new drug called BG-C9074, designed to seek out and attack cancer cells while sparing healthy ones. It is for people with advanced solid tumors that have not responded to standard treatments. The study will test the drug alone and in combination with…

This study tests if a shot under the skin works as well as an IV drip for a cancer drug (tislelizumab) combined with chemotherapy in adults with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. About 351 participants will recei…

This study tests a new drug, sonrotoclax, combined with antibody therapy for adults with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma. About 630 participants will be randomly assigned to receive either the new combination or a standard trea…

This early-phase study tests a new experimental drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The main goals are to check the drug's safety, find the best dose, and see if …

This study tests whether adding sonrotoclax to the standard drug zanubrutinib helps adults with mantle cell lymphoma that has returned or stopped responding to prior treatments. About 300 participants will receive either the combination or a placebo plus zanubrutinib. The main go…

This early-phase study tests a new drug called BG-C137 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to cells with a specific marker (FGFR2b). The main goals are to check safety…

This early-stage study tests a new drug called BG-A3004 for safety and how the body processes it. It includes healthy volunteers and people with immune-related skin conditions. Participants receive either the drug or a placebo, and researchers monitor side effects and drug levels…